FITME
File: INNEST/2024/240
Duration:
According to the WHO, obesity is a growing pandemic associated with risks such as metabolic syndrome, respiratory diseases, certain types of cancer and musculoskeletal disorders, impacting quality of life and generating high socio-health costs. In this context, Sabartech, specialised in genomic and microbiota analysis, participates in the FITME project (Development of an advanced methodology for comprehensive morphofunctional assessment in obese patients) in the development of an advanced methodology for patients with obesity.
This project, coordinated by the Instituto de Biomecánica de Valencia (IBV), aims to create a multiscale model that combines morphofunctional and omic variables to estimate in a personalised and accurate way the body composition and distribution, as well as the metabolic risk in patients with obesity.
The proposed methodology will be objective, agile, sustainable, non-invasive and not dependent on experts, facilitating its integration into the healthcare environment. SABARTECH will provide its experience in genomic and microbiota analysis, contributing to the development of tools that allow a comprehensive and personalised assessment of patients.
With this initiative, SABARTECH SL continues to consolidate its position as a leading company in the biotechnological field of prevenomics, contributing to the development of advanced methodologies that improve people’s quality of life and strengthen the innovation ecosystem in the Valencian Community.
In order to achieve the purpose of the project, the following specific scientific, technological and technical objectives are proposed:
From a strategic point of view, it is expected that the results of the project will have a positive impact on the social and healthcare infrastructure for the management of obesity, as well as favouring the generation of knowledge for the improvement of products and services in this context. This is based on the following specific impact objectives:
The FITME project has received a total funding of €811,986.47 from the Valencian Innovation Agency (AVI), distributed in three annual instalments until 2026. This investment will allow progress in the research and development of innovative solutions for the treatment of obesity, a condition that affects a significant percentage of the population and represents a challenge for health systems.
Coordinator:
Instituto de Biomecánica de Valencia (IBV)
Collaborating companies and entities
Sabartech S.L.
Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana INCLIVA
Clinicas Ascires (ECG MEDICAS.L.)
EXPEDIENT Nº: IMIDTA/2023/43.
PROGRAM: SME R&D PROJECTS (PIDI-CV) 2023
PROJECT: AIG-SPORT – THE NEXT GENERATION OF SPORT PERFORMANCE (AIG-SPORT)
OBJECTIVES: The generation of a new model of 5P SPORTS TECHNOLOGY to revolutionise professional and amateur sport.
RESULTS ACHIEVED: A software focused on sports performance called AIG-SPORT that aims to bring science closer to athletes through guidelines for the improvement of sports performance, athletes’ brands, the prevention of injuries related to exercise and training, the personalisation of food and supplementation plans in a much more precise way.
THIS PROJECT IS SUPPORTED BY THE EUROPEAN UNION AS IT HAS BEEN SELECTED IN THE FEDER OPERATIONAL PROGRAMME FOR THE VALENCIAN COMMUNITY 2021-2027.
Expedient Nº: INNEST/2021/292
Project: INTELLIGENT PLATFORM FOR EARLY DETECTION, DIAGNOSIS AND MONITORING OF SARCOPENIA (iSARC-GENETICS)
Supported by Agència Valenciana de la Innovació (AVI)